Research progress of SPARC in esophageal cancer

doi:10.3760/cma.j.issn.1673-422X.2014.12.013

Abstract

HUANG Hai-Bo, ZHAO Yan-Yang, SHU Jun. Research progress of SPARC in esophageal cancer[J]. Journal of International Oncology, 2014, 41(12): 918-921.

［1］许牧, 曹毅, 蒋蒙蒙, 等. miR495、miR551a 靶向干扰 PRL3 表达抑制胃癌腹膜转移［J］. 世界华人消化杂志, 2013, 21(18): 16931700. ［2］郁婷婷, 李硕, 傅敏根, 等. miR130b在食管鳞癌中的表达及对食管鳞癌细胞增殖和迁移的影响［J］. 世界华人消化杂志, 2013, 21(18): 16851692. ［3］ Termine JD, Kleinman HK, Whitson SW, et al. Osteonectin, a bonespecific protein linking mineral to collagen［J］. Cell, 1981, 26(1): 99105. ［4］ Chlenski A, Cohn SL. Modulation of matrix remodeling by SPARC in neoplastic progression［J］. Semin Cell Dev Biol, 2010, 21(1): 5565. ［5］ Nagaraju GP, Sharma D. Anticancer role of SPARC, an inhibitor of adipogenesis［J］. Cancer treat Rev, 2011, 37(7): 559566. ［6］ Porte H, Chastre E, Prevot S, et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin3 and BM40/SPARC genes［J］. Int J Cancer, 1995, 64(1): 7075. ［7］ Ledda MF, Adris S, Bravo AI, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells［J］. Nature medicine, 1997, 3(2): 171176. ［8］ Yamashita K, Upadhay S, Mimori K, et al. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression［J］. Cancer, 2003, 97(10): 24122419. ［9］ Porte H, Triboulet JP, Kotelevets L, et al. Overexpression of stromelysin3, BM40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis［J］. Clinical cancer research, 1998, 4(6): 13751382. ［10］ Brabender J, Lord RV, Metzger R, et al. Differential SPARC mRNA expression in Barrett′s oesophagus［J］. Br J cancer, 2003, 89(8): 15081512. ［11］车轶群, 王海, 齐军, 等. 食管鳞癌组织中 SPARC 蛋白表达的临床意义［J］. 中国肿瘤临床, 2006, 33(2): 6163. ［12］冯丹, 蔡建, 张颖一, 等. SPARC 在恶性肿瘤中的研究进展［J］. 医学研究杂志, 2012, 40(10): 1316. ［13］高杨, 李岩, 周海英, 等. 酸性富含半胱氨酸分泌型蛋白的表达与食管鳞状细胞癌患者临床特征的关系［J］. 世界华人消化杂志, 2013, 21(21): 20812085. ［14］杨锡贵, 姜超, 刘封, 等. SPARC 蛋白在食管鳞癌组织中的表达及临床意义［J］. 肿瘤防治研究, 2012, 39(10):12401242. ［15］ Che Y, Luo A, Wang H, et al. The differential expression of SPARC in esophageal squamous cell carcinoma［J］. Int J Mol Med, 2006, 17(6): 10271033. ［16］庞霞, 李晟磊, 赵志华, 等. TGFβ1、TIEG1 和 Stathmin 蛋白在食管鳞状细胞癌组织中的表达及临床意义［J］. 世界华人消化杂志, 2013, 21(4): 327331. ［17］杨迷玲, 翟丽丽, 马丽华, 等. SPARC 和 VEGF 在胃癌组织中的表达及与血管生成的关系［J］. 诊断病理学杂志, 2012, 19(1): 5255. ［18］杨锡贵, 姜超, 刘封, 等. 食管鳞状细胞癌组织中酸性富含半胱氨酸分泌型蛋白的表达与生存的相关性［J］. 中华消化杂志, 2013, 33(3): 197198. ［19］ Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy［J］. Drug Resist Updat, 2008, 11(6): 231246. ［20］ Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nabpaclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase Ⅰ/Ⅱtrial［J］. J Clin Oncol, 2011, 29(34): 45484554. ［21］ AlBatran SE, Geissler M, Seufferlein T, et al. Nabpaclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action［J］. Oncol Res Treat, 2014, 37(3): 128134. ［22］ Gradishar WJ, Tjulandin S, Davidson N, et al. Phase Ⅲ trial of nanoparticle albuminbound paclitaxel compared with polyethylated castor oilbased paclitaxel in women with breast cancer［J］. J Clin Oncol, 2005, 23(31): 77947803.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[12]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[13]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[14]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[15]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.

Research progress of SPARC in esophageal cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments